Indeed, the authors reported that increasing the PERK/NRF2 signaling pathway was the origin of a developed cross-resistance to chemotherapy in human cell lines originating from breast cancer, colon cancer, and osteosarcoma. This evidence concerns the gene NFE2L2 and osteosarcoma.